NASDAQ:EXELExelixis Stock Price, Forecast & News

Exelixis' stock was trading at $17.32 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EXEL shares have increased by 38.1% and is now trading at $23.9150. View which stocks have been most impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Exelixis.

Exelixis is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Exelixis.

Exelixis, Inc. (NASDAQ:EXEL) issued its quarterly earnings results on Tuesday, May, 5th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.13 by $0.02. The biotechnology company had revenue of $226.90 million for the quarter, compared to the consensus estimate of $216.64 million. Exelixis had a return on equity of 18.01% and a net margin of 30.01%. The company's quarterly revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.27 EPS. View Exelixis' earnings history.

Exelixis updated its FY 2020 After-Hours earnings guidance on Tuesday, May, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $850-900 million, compared to the consensus revenue estimate of $886.93 million.

12 analysts have issued twelve-month price targets for Exelixis' stock. Their forecasts range from $21.00 to $40.00. On average, they expect Exelixis' share price to reach $28.92 in the next year. This suggests a possible upside of 20.9% from the stock's current price. View analysts' price targets for Exelixis.

Media coverage about EXEL stock has been trending negative this week, InfoTrie reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Exelixis earned a news impact score of -2.1 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Exelixis.

Exelixis saw a increase in short interest in June. As of June 30th, there was short interest totaling 16,210,000 shares, an increase of 8.9% from the June 15th total of 14,880,000 shares. Based on an average daily volume of 3,610,000 shares, the short-interest ratio is presently 4.5 days. Approximately 5.5% of the shares of the stock are short sold. View Exelixis' Current Options Chain.

Some companies that are related to Exelixis include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Intel (INTC), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Exelixis' stock is owned by a number of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.06%) and IBM Retirement Fund (0.00%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View institutional ownership trends for Exelixis.

EXEL stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos, and Vincent T Marchesi. View insider buying and selling activity for Exelixis.

EXEL stock was acquired by a variety of institutional investors in the last quarter, including IBM Retirement Fund. View insider buying and selling activity for Exelixis.

Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EXEL stock can currently be purchased for approximately $23.92.

Exelixis has a market capitalization of $7.33 billion and generates $967.78 million in revenue each year. The biotechnology company earns $321.01 million in net income (profit) each year or $1.02 on an earnings per share basis. Exelixis employs 484 workers across the globe.

The official website for Exelixis is www.exelixis.com.

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]